Press Releases

Insert text here...

04/04/2022

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease

PRX-102 successfully met the primary endpoint on kidney function in active control, non-inferiority study vs. agalsidase beta

Topline results demonstrated a favorable tolerability and immunogenicity profile for PRX-102 BLA resubmission planned for the second half of 2022

Thoughts from our Leaders

Recent Articles

Join our rare community

Join us online and take part in the global conversation about rare diseases.

Facebook

Instagram

LinkedIn

Twitter

YouTube

Learn More about Chiesi Global Rare Diseases

See
Products

Discover treatments that are helping to change the rare disease landscape.

Read More

Find Treatments

Find
Treatments

Discover innovative treatments that are helping to change the rare disease landscape.

Read more

See
Pipeline

Explore rare disease therapies under development.

Read More

See Pipeline

See
Pipeline

Explore novel therapies under development.

Read more

For Healthcare Professionals

For Healthcare
Professionals

From research to results, see how we’re committed to helping you help your patients.

Read More

For Patients

For
Patients

Find support, advocacy, and what we value most—a caring community.

Read More